

Pharmacy Drug Policy & Procedure

Policy Name: Mozobil (plerixafor) Policy #: 2449P

Purpose of the Policy

The purpose of this policy is to establish the criteria for coverage of Mozobil.

Statement of the Policy

Health Alliance Medical Plans will approve the use of Mozobil under the specialty medical benefit when the following criteria have been met.

Criteria

- 1. Coverage Criteria for Mobilization of Hematopoietic Stem Cells for Collection Prior to Autologous Transplantation
- 1.1 Diagnosis of Non-Hodgkin's lymphoma, or multiple myeloma, or germ cell tumors
- 1.2 Prescribed by an oncologist (cancer doctor) or hematologist (blood doctor)
- 1.3 Mozobil will be used with a granulocyte colony-stimulating factor (G-CSF, such as Neupogen)

2. Approval Time

2.1 6 months (maximum of four visits per lifetime)

CPT Codes	
HCPCS Codes	
J2562	Injection, plerixafor, 1mg

References

- 1. Mozobil [package insert]. Cambridge, MA: Genzyme Corporation; September 2023.
- 2. DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E *et al.* Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. *J Clin Oncol* 2009; 27: 4767–4773.
- 3. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL *et al.* Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. *Blood* 2009; 113: 5720
- 4. Horwitz ME, Long, G, Holman P, et al. Efficacy and safety of hematopoietic stem cell remobilization with plerixafor+G-CSF in adult patients with germ cell tumors. *Bone Marrow Transplantation* (2012) 47, 1283-86.

Created Date: 02/03/16 Effective Date: 02/03/16 Posted to Website: 01/01/22 Revision Date: 02/05/25

DISCLAIMER

This Medical Policy has been developed as a guide for determining medical necessity. The process of medical necessity review also entails review of the most recent literature and physician review. Medical Policy is not intended to dictate to providers how to practice medicine. Providers are expected to exercise their medical judgment in providing the most appropriate care. Health Alliance encourages input from providers when developing and implementing medical policies. Benefit determinations are based on applicable contract language in the member's Policy/ Subscription Certificate/ Summary Plan Description. This Medical Policy does not guarantee coverage. There may be a delay between the revision of this policy and the posting on the web. Please contact the Health Alliance Customer Service Department at 1-800-851-3379 for verification of coverage.